/PRNewswire/ On July 11, 2022, VenusP-ValveTM, Venus Medtech s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was.
HANGZHOU, China, July 13, 2022 /PRNewswire/ On July 11, 2022, VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was approved by China's National Medical Products Administration (NMPA) for the treatment of severe pulmonary regurgitation (3+) in patients after congenital heart defects (CHD) procedure with native right ventricular outflow tract (RVOT). The approval has made VenusP-ValveTM the first TPVR product to be marketed in China, marking another milestone following its CE MDR approval. As the first self-expanding TPVR product approved for marketing in both China and Europe, VenusP-ValveTM sets itself apart with remarkable clinical value. Uniquely designed with both flared ends, the product ensures the blood flow of branchial artery with bare stents at the outflow end. It provides a stable multi-point anchoring system and enables easy delivery, with no need for pre-stenting before the procedure. Available i
HANGZHOU, China, July 13, 2022 /PRNewswire/ On July 11, 2022, VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was approved
Guangzhou is considering implementing a new green card system that will make it easier for high-level talent to relocate and conduct business in the city.